A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma.

Olga VornicovaNissim HaimBar-Sela Gil

Published in: Cancer chemotherapy and pharmacology (2019)

According to our preliminary experience, adding olaratumab to doxorubicin and ifosfamide is active and its safety profile is comparable to that of doxorubicin and ifosfamide alone in MSTS.

Keyphrases

drug delivery
cancer therapy